MedTrace Logo

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

NCT04339140 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-12-11

Study results available
· View outcomes & findings →

Summary

This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer.

* The name of the study drug involved in this study is:
* Zafirlukast

Conditions

Interventions

DRUG

Zafirlukast

Oral tablets, 2x daily for 28 day cycle up to 1 year

Sponsors & Collaborators

Principal Investigators

  • Rushad Patell, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-24
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04339140 on ClinicalTrials.gov